We acknowledge that exogenous FVIII therapy for hemophilia A was first introduced in the late 1960s, when cryoprecipitates and plasma-derived concentrates were pioneeringly utilized [58,59], but the introduction of recombinant factor VIII and its subsequent influence on the prognosis and survival rate of these newborns dates to the late 1980s and early 1990s [60], which significantly influences our reasoning. Here, F8 is linked to hemophilia A.